Anson Smith, MD
Interventional Cardiology · Pittsburgh, PANPI 1629044425
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,636 of the $18,404 with a category attached, or 63.2%. 19 manufacturers reported payments, led by Abbott at 39.4% of the total.
Across 133 payments — averaging $138.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Ancora Heart, Inc.$4K
- Edwards Lifesciences$3K
- Abiomed$1K
- Inari Medical, Inc.$858
- Boston Scientific$567
- plus $1K from 13 others
Across 161 payments — averaging $3104.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$499K
- Medtronic$1K
What the payments were for
- Consulting fees$1,0005%
- Travel & lodging$11,63663%
- Food & beverage$5,76831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 55 | $7,244 |
| Ancora Heart, Inc. | 14 | $4,021 |
| Edwards Lifesciences | 16 | $3,228 |
| Abiomed | 9 | $1,343 |
| Inari Medical, Inc. | 3 | $858 |
| Boston Scientific | 5 | $567 |
| W. L. Gore & Associates, Inc. | 9 | $317 |
| Cardiac Dimensions, Inc. | 3 | $223 |
| Shockwave Medical, Inc | 1 | $134 |
| Teleflex LLC | 1 | $98 |
| Amgen | 4 | $87 |
| E.r. Squibb & Sons, L.L.C. | 3 | $63 |
| Novartis | 3 | $48 |
| Heartflow, Inc. | 2 | $46 |
| Livanova USA, Inc. | 1 | $40 |
| Medtronic | 1 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Cardiva Medical, Inc. | 1 | $23 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AccuCinch$3,920
- MitraClip$3,184
- EVOQUE$1,668
- Impella$1,013
- TRICLIP$1,000
- Edwards SAPIEN 3 Transcatheter Heart Valve$986
- FlowTriever$747
- ClotTriever$747
- Mitra Clip system$495
- MitraClip System$329
- Xience Sierra Coronary Stent System$315
- GORE CARDIOFORM Septal Occluder$150
- GENERAL - THERAPIES$140
- GENERAL - STRUCTURAL HEART$140
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$134
- CROSSBOSS$125
- PASCAL$116
How this compares
$18,404 in reported general payments places this provider in the 70th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 197 | $233,630 |
| EliquisApixaban | 207 | $221,124 |
| EntrestoSacubitril/Valsartan | 86 | $127,867 |
| Repatha SureclickEvolocumab | 177 | $119,179 |
| XareltoRivaroxaban | 30 | $37,949 |
| BrilintaTicagrelor | 18 | $16,274 |
| Icosapent Ethyl | 17 | $6,047 |
| Repatha SyringeEvolocumab | 11 | $5,964 |
| Rosuvastatin Calcium | 328 | $5,746 |
| Atorvastatin Calcium | 318 | $4,166 |
| Ezetimibe | 174 | $4,106 |
| Metoprolol Succinate | 223 | $3,819 |
| Bumetanide | 53 | $3,584 |
| Carvedilol | 276 | $2,873 |
| ClopidogrelClopidogrel Bisulfate | 121 | $1,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $25 | $233,630197 claims |
| PfizerEliquis | $15 | $221,124207 claims |
| NovartisEntresto | $48 | $127,86786 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Pittsburgh
- David LasordaPittsburgh$271K
- Ramzi KhalilPittsburgh$217K
- Ryan ZuzekPittsburgh$152K
- Catalin TomaPittsburgh$120K
- Dustin KlinerPittsburgh$73K
- Adnan KhalifPittsburgh$39K
- Saad TabbaraPittsburgh$28K
- Jeffrey FowlerPittsburgh$26K
- Marinos CharalambousPittsburgh$25K
- Nishant SethiScranton$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.